Revenue
5Y CAGR +152.6%10Y CAGR +56.9%No quarters filed for this figure.
Form 4 transactions by trade date, as filed; latest on file 2026-09-08.
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Bar = where today’s multiple sits in ASND’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).
No quarters filed for this figure.
No quarters filed for this figure.
No quarters filed for this figure.
FY25: operating cash flow $61M, capex —
No quarters filed for this figure.
No quarters filed for this figure.
No quarters filed for this figure.
Ascendis Pharma A/S is a global biopharmaceutical company focused on developing and commercializing therapies for rare endocrine diseases and other serious chronic conditions. The company uses its proprietary TransCon technology platform to create medicines designed to improve treatment delivery and address unmet medical needs. Its current portfolio includes marketed products for growth hormone deficiency and chronic hypoparathyroidism, along with clinical-stage programs in endocrinology rare disease and oncology. Headquartered in Copenhagen, Denmark, Ascendis Pharma operates across Europe and the United States, combining research, development, and commercialization capabilities to support patients, physicians, and healthcare systems in specialized therapeutic areas.
Hellerup, Denmark·1,189 employees·Biotechnology·ascendispharma.com·As of Oct 28, 2026
12 of the 193 ETFs ChartRow carries live hold ASND. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).
| Fund | Name | Filed weight |
|---|---|---|
| IBB | iShares Biotechnology ETF | 1.3% |
| IWP | iShares Russell Mid-Cap Growth ETF | 0.3% |
| IWR | iShares Russell Midcap ETF | 0.1% |
| IWF | iShares Russell 1000 Growth ETF | 0.0% |
| VONG | Vanguard Russell 1000 Growth ETF | 0.0% |
| ONEQ | Fidelity Nasdaq Composite Index ETF | 0.0% |
| IWB | iShares Russell 1000 ETF | 0.0% |
| VONE | Vanguard Russell 1000 ETF | 0.0% |
| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +12.61% | -1.13% |
| JNJ | Johnson & Johnson | +9.05% | -1.36% |
| ABBV | AbbVie Inc. | +2.59% | -0.59% |
| MRK | Merck & Co. Inc. | -1.77% | -0.75% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | -2.93% | -5.42% |
| NVS | Novartis AG | +5.65% | -0.67% |
| TMO | Thermo Fisher Scientific Inc. | -0.47% | -0.66% |
| AMGN | Amgen Inc. | +5.88% | -0.95% |